Provectus Biopharmaceuticals Stock Performance
| PVCT Stock | USD 0.04 0 4.65% |
The company holds a Beta of -0.74, which implies possible diversification benefits within a given portfolio. As returns on the market increase, returns on owning Provectus Biopharmaceutica are expected to decrease at a much lower rate. During the bear market, Provectus Biopharmaceutica is likely to outperform the market. At this point, Provectus Biopharmaceutica has a negative expected return of -0.28%. Please make sure to check Provectus Biopharmaceutica's total risk alpha, kurtosis, as well as the relationship between the Kurtosis and day typical price , to decide if Provectus Biopharmaceutica performance from the past will be repeated at some point in the near future.
Risk-Adjusted Performance
Weakest
Weak | Strong |
Over the last 90 days Provectus Biopharmaceuticals has generated negative risk-adjusted returns adding no value to investors with long positions. In spite of fragile performance in the last few months, the Stock's fundamental indicators remain comparatively stable which may send shares a bit higher in March 2026. The newest uproar may also be a sign of mid-term up-swing for the firm private investors. ...more
Provectus |
Provectus Biopharmaceutica Relative Risk vs. Return Landscape
If you would invest 6.10 in Provectus Biopharmaceuticals on November 15, 2025 and sell it today you would lose (1.60) from holding Provectus Biopharmaceuticals or give up 26.23% of portfolio value over 90 days. Provectus Biopharmaceuticals is currently does not generate positive expected returns and assumes 6.8108% risk (volatility on return distribution) over the 90 days horizon. In different words, 61% of otc stocks are less volatile than Provectus, and 99% of all traded equity instruments are projected to make higher returns than the company over the 90 days investment horizon. Expected Return |
| Risk |
Provectus Biopharmaceutica Target Price Odds to finish over Current Price
The tendency of Provectus OTC Stock price to converge on an average value over time is a known aspect in finance that investors have used since the beginning of the stock market for forecasting. However, many studies suggest that some traded equity instruments are consistently mispriced before traders' demand and supply correct the spread. One possible conclusion to this anomaly is that these stocks have additional risk, for which investors demand compensation in the form of extra returns.
| Current Price | Horizon | Target Price | Odds to move above the current price in 90 days |
| 0.04 | 90 days | 0.04 | about 97.0 |
Based on a normal probability distribution, the odds of Provectus Biopharmaceutica to move above the current price in 90 days from now is about 97.0 (This Provectus Biopharmaceuticals probability density function shows the probability of Provectus OTC Stock to fall within a particular range of prices over 90 days) .
Provectus Biopharmaceutica Price Density |
| Price |
Predictive Modules for Provectus Biopharmaceutica
There are currently many different techniques concerning forecasting the market as a whole, as well as predicting future values of individual securities such as Provectus Biopharmaceutica. Regardless of method or technology, however, to accurately forecast the otc stock market is more a matter of luck rather than a particular technique. Nevertheless, trying to predict the otc stock market accurately is still an essential part of the overall investment decision process. Using different forecasting techniques and comparing the results might improve your chances of accuracy even though unexpected events may often change the market sentiment and impact your forecasting results.Sophisticated investors, who have witnessed many market ups and downs, anticipate that the market will even out over time. This tendency of Provectus Biopharmaceutica's price to converge to an average value over time is called mean reversion. However, historically, high market prices usually discourage investors that believe in mean reversion to invest, while low prices are viewed as an opportunity to buy.
Provectus Biopharmaceutica Risk Indicators
For the most part, the last 10-20 years have been a very volatile time for the stock market. Provectus Biopharmaceutica is not an exception. The market had few large corrections towards the Provectus Biopharmaceutica's value, including both sudden drops in prices as well as massive rallies. These swings have made and broken many portfolios. An investor can limit the violent swings in their portfolio by implementing a hedging strategy designed to limit downside losses. If you hold Provectus Biopharmaceuticals, one way to have your portfolio be protected is to always look up for changing volatility and market elasticity of Provectus Biopharmaceutica within the framework of very fundamental risk indicators.α | Alpha over Dow Jones | -0.27 | |
β | Beta against Dow Jones | -0.74 | |
σ | Overall volatility | 0.01 | |
Ir | Information ratio | -0.06 |
Provectus Biopharmaceutica Alerts and Suggestions
In today's market, stock alerts give investors the competitive edge they need to time the market and increase returns. Checking the ongoing alerts of Provectus Biopharmaceutica for significant developments is a great way to find new opportunities for your next move. Suggestions and notifications for Provectus Biopharmaceutica can help investors quickly react to important events or material changes in technical or fundamental conditions and significant headlines that can affect investment decisions.| Provectus Biopharmaceutica generated a negative expected return over the last 90 days | |
| Provectus Biopharmaceutica has high historical volatility and very poor performance | |
| Provectus Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Provectus Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Provectus Biopharmaceuticals currently holds about 84.27 K in cash with (1.01 M) of positive cash flow from operations. |
Provectus Biopharmaceutica Fundamentals Growth
Provectus OTC Stock prices reflect investors' perceptions of the future prospects and financial health of Provectus Biopharmaceutica, and Provectus Biopharmaceutica fundamentals are critical determinants of its market performance. Overall, investors pay close attention to revenue and earnings growth, profit margins, and debt levels. These fundamentals can have a significant impact on Provectus OTC Stock performance.
| Return On Asset | -1.85 | |||
| Operating Margin | (4.77) % | |||
| Current Valuation | 46.73 M | |||
| Shares Outstanding | 419.55 M | |||
| Price To Earning | (0.48) X | |||
| Price To Book | 5.44 X | |||
| Price To Sales | 55.94 X | |||
| EBITDA | (4.56 M) | |||
| Cash And Equivalents | 84.27 K | |||
| Total Debt | 2.29 M | |||
| Debt To Equity | 0.25 % | |||
| Book Value Per Share | (0.02) X | |||
| Cash Flow From Operations | (1.01 M) | |||
| Earnings Per Share | (0.01) X | |||
| Total Asset | 3.51 M | |||
| Retained Earnings | (180.8 M) | |||
| Current Asset | 14.72 M | |||
| Current Liabilities | 4.12 M | |||
About Provectus Biopharmaceutica Performance
Assessing Provectus Biopharmaceutica's fundamental ratios provides investors with valuable insights into Provectus Biopharmaceutica's financial health and overall profitability. This information is crucial for making informed investment decisions. A high ROA would indicate that the Provectus Biopharmaceutica is effectively leveraging its assets and equity to generate significant profits, making it an appealing investment. Conversely, low Return on Assets could signal underlying management issues in assets and equity, indicating a necessity for operational refinements. Please also refer to our technical analysis and fundamental analysis pages.
Provectus Biopharmaceuticals, Inc., a clinical-stage biotechnology company, engages in developing immunotherapy medicines based on halogenated xanthenes. Provectus Biopharmaceuticals, Inc. was incorporated in 2002 and is based in Knoxville, Tennessee. Provectus Pharma operates under Biotechnology classification in the United States and is traded on OTC Exchange. It employs 4 people.Things to note about Provectus Biopharmaceutica performance evaluation
Checking the ongoing alerts about Provectus Biopharmaceutica for important developments is a great way to find new opportunities for your next move. OTC Stock alerts and notifications screener for Provectus Biopharmaceutica help investors to be notified of important events, changes in technical or fundamental conditions, and significant headlines that can affect investment decisions.| Provectus Biopharmaceutica generated a negative expected return over the last 90 days | |
| Provectus Biopharmaceutica has high historical volatility and very poor performance | |
| Provectus Biopharmaceutica has some characteristics of a very speculative penny stock | |
| Provectus Biopharmaceutica has a very high chance of going through financial distress in the upcoming years | |
| Provectus Biopharmaceuticals currently holds 2.29 M in liabilities with Debt to Equity (D/E) ratio of 0.25, which may suggest the company is not taking enough advantage from borrowing. Provectus Biopharmaceutica has a current ratio of 0.26, indicating that it has a negative working capital and may not be able to pay financial obligations when due. Debt can assist Provectus Biopharmaceutica until it has trouble settling it off, either with new capital or with free cash flow. So, Provectus Biopharmaceutica's shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Provectus Biopharmaceutica sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Provectus to invest in growth at high rates of return. When we think about Provectus Biopharmaceutica's use of debt, we should always consider it together with cash and equity. | |
| Net Loss for the year was (5.54 M) with profit before overhead, payroll, taxes, and interest of 0. | |
| Provectus Biopharmaceuticals currently holds about 84.27 K in cash with (1.01 M) of positive cash flow from operations. |
- Analyzing Provectus Biopharmaceutica's financial statements, including its income statement, balance sheet, and cash flow statement, helps in understanding its overall financial health and growth potential.
- Getting a closer look at valuation ratios like price-to-earnings (P/E) ratio, price-to-sales (P/S) ratio, and price-to-book (P/B) ratio help in understanding whether Provectus Biopharmaceutica's stock is overvalued or undervalued compared to its peers.
- Examining Provectus Biopharmaceutica's industry or sector and how it is performing can give you an idea of its growth potential and how it is positioned relative to its competitors.
- Evaluating Provectus Biopharmaceutica's management team can have a significant impact on its success or failure. Reviewing the track record and experience of Provectus Biopharmaceutica's management team can help you assess the OTC Stock's leadership.
- Pay attention to analyst opinions and ratings of Provectus Biopharmaceutica's otc stock. These opinions can provide insight into Provectus Biopharmaceutica's potential for growth and whether the stock is currently undervalued or overvalued.
Additional Tools for Provectus OTC Stock Analysis
When running Provectus Biopharmaceutica's price analysis, check to measure Provectus Biopharmaceutica's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Provectus Biopharmaceutica is operating at the current time. Most of Provectus Biopharmaceutica's value examination focuses on studying past and present price action to predict the probability of Provectus Biopharmaceutica's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Provectus Biopharmaceutica's price. Additionally, you may evaluate how the addition of Provectus Biopharmaceutica to your portfolios can decrease your overall portfolio volatility.